ConductScience.org, home

Paper42279367

Risk of Malignancy with Immunosuppressive Drugs Used in Organ Transplants Compared to Those Used for Non-Transplant Indications.

Haines C and 6 others. Cancers (Basel), 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Risk of Malignancy with Immunosuppressive Drugs Used in Organ Transplants Compared to Those Used for Non-Transplant Indications. Papers, record 42279367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42279367

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Risk of Malignancy with Immunosuppressive Drugs Used in Organ Transplants Compared to Those Used for Non-Transplant Indications.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Haines CConnorhttps://orcid.org/0009-0008-4131-6091
2Walton ZZacharyhttps://orcid.org/0009-0002-0749-1079
3Curnutt IIanhttps://orcid.org/0009-0005-4511-3142
4Golovko GGeorge
5Kuo YFYong-Fanghttps://orcid.org/0000-0003-1927-0927
6Rastellini CCristiana
7Cicalese LLuca

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122955152Biologic therapy.J Infus Nurs2012https://conductscience.org/library/papers/22955152PubMed
237650722Comparison of 2 Immunosuppression Minimization Strategies in Kidney Transplantation: The ALLEGRO Trial.Transplantation2024https://conductscience.org/library/papers/37650722PubMed
318498314Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression.Transpl Int2008https://conductscience.org/library/papers/18498314PubMed
410699159Improved graft survival after renal transplantation in the United States, 1988 to 1996.N Engl J Med2000https://conductscience.org/library/papers/10699159PubMed
533715321Cervical dysplasia after renal transplantation: A retrospective cohort study.Turk J Obstet Gynecol2021https://conductscience.org/library/papers/33715321PubMed
610580071Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.N Engl J Med1999https://conductscience.org/library/papers/10580071PubMed
721466650Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study.Am J Transplant2011https://conductscience.org/library/papers/21466650PubMed
838725273Therapeutic drug monitoring in kidney and liver transplantation: current advances and future directions.Expert Rev Clin Pharmacol2024https://conductscience.org/library/papers/38725273PubMed
940211394Natural killer cells: the immune frontline against circulating tumor cells.J Exp Clin Cancer Res2025https://conductscience.org/library/papers/40211394PubMed
1025126214The value of biologics.Am Health Drug Benefits2008https://conductscience.org/library/papers/25126214PubMed
1114444006The effects of 6-mercaptopurine on homograft reactions.J Clin Invest1960https://conductscience.org/library/papers/14444006PubMed
1221832958Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial.Transplantation2011https://conductscience.org/library/papers/21832958PubMed
1340647460Immunosuppressant Drug Specific Risk of Malignancy After Organ Transplantation: A Population-Based Analysis of Texas Medicare Beneficiaries.Cancers (Basel)2025https://conductscience.org/library/papers/40647460PubMed
1431609477Mycophenolic acid is a drug with the potential to be repurposed for suppressing tumor growth and metastasis in osteosarcoma treatment.Int J Cancer2020https://conductscience.org/library/papers/31609477PubMed
1514508356Primary brain lymphomas after kidney transplantation: presentation and outcome.Transplantation2003https://conductscience.org/library/papers/14508356PubMed
1632522746Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.Clin Microbiol Rev2020https://conductscience.org/library/papers/32522746PubMed
1734769123Biological Therapies in the Treatment of Cancer-Update and New Directions.Int J Mol Sci2021https://conductscience.org/library/papers/34769123PubMed
1810739783Differences in quality of life across renal replacement therapies: a meta-analytic comparison.Am J Kidney Dis2000https://conductscience.org/library/papers/10739783PubMed
1925062652Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.Clin Ther2014https://conductscience.org/library/papers/25062652PubMed
2041227204Tacrolimus-Sirolimus Combined Exposure and Acute Rejection in Kidney Transplant Recipients Undergoing Early Conversion to Sirolimus: A Multicenter Retrospective Cohort Threshold Analysis.J Clin Med2025https://conductscience.org/library/papers/41227204PubMed

See all 39 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42279367

GET https://conductscience.org/api/papers/v1/42279367/references?page=2